- Home
- ZBIO vs ABEO Comparison
ZBIO vs ABEO Comparison
Compare ZBIO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- ABEO
- Stock Information
- Founded
- ZBIO 2019
- ABEO N/A
- Country
- ZBIO United States
- ABEO United States
- Employees
- ZBIO N/A
- ABEO N/A
- Industry
- ZBIO
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- ZBIO
- ABEO Health Care
- Exchange
- ZBIO NYSE
- ABEO Nasdaq
- Market Cap
- ZBIO 268.7M
- ABEO 253.0M
- IPO Year
- ZBIO 2024
- ABEO 1980
- Fundamental
- Price
- ZBIO $7.83
- ABEO $5.78
- Analyst Decision
- ZBIO Strong Buy
- ABEO Strong Buy
- Analyst Count
- ZBIO 6
- ABEO 4
- Target Price
- ZBIO $29.20
- ABEO $17.25
- AVG Volume (30 Days)
- ZBIO 207.0K
- ABEO 271.9K
- Earning Date
- ZBIO 03-04-2025
- ABEO 03-17-2025
- Dividend Yield
- ZBIO N/A
- ABEO N/A
- EPS Growth
- ZBIO N/A
- ABEO N/A
- EPS
- ZBIO N/A
- ABEO N/A
- Revenue
- ZBIO N/A
- ABEO N/A
- Revenue This Year
- ZBIO N/A
- ABEO N/A
- Revenue Next Year
- ZBIO N/A
- ABEO $15,721.96
- P/E Ratio
- ZBIO N/A
- ABEO N/A
- Revenue Growth
- ZBIO N/A
- ABEO 147.52
- 52 Week Low
- ZBIO $5.83
- ABEO $3.05
- 52 Week High
- ZBIO $26.25
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- ABEO 52.03
- Support Level
- ZBIO N/A
- ABEO $5.79
- Resistance Level
- ZBIO N/A
- ABEO $6.16
- Average True Range (ATR)
- ZBIO 0.00
- ABEO 0.23
- MACD
- ZBIO 0.00
- ABEO 0.02
- Stochastic Oscillator
- ZBIO 0.00
- ABEO 50.00
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.